Cohort Study of Airway Microecology and the Pathogenesis and Evolution of Chronic Obstructive Pulmonary Disease
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study will last for 5 years (2021.2.25-2025.12.31). 210 patients (70 cases in each group) will be enrolled in this study. Eight centers in China will participate in the study. The patients will be treated with bronchoscopy alveolar lavage, and 60 ml of bronchoalveolar lavage fluid will be collected for the next-generation sequencing of airway microorganisms. The patients will be followed up for 4 years to observe the changes of lung function, Fractional exhaled nitric oxide (FENO) and clinical symptoms.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Have the ability to communicate orally or in writing and sign an informed consent form;
• Age from 18 to 70 years (the age of patients with mild to moderate COPD \<75 years), regardless of gender;
• Meet the above-mentioned early diagnosis criteria for high-risk patients with COPD/early-stage COPD/mild to moderate COPD.
Locations
Other Locations
China
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University
RECRUITING
Shanghai
Contact Information
Primary
Junjie Yun, master
379215100@qq.com
021-23271699
Time Frame
Start Date:2021-02-26
Estimated Completion Date:2025-12-31
Participants
Target number of participants:210
Treatments
COPD high-risk patients
age \<70 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
Early-stage COPD patients
those who are younger than 70 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:~1. Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) \<lower limit of normal value (LLN, 80%);~2. CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;~3. FEV1 drops rapidly (≥60 mL/year);
patients with mild to moderate COPD
Patients with mild to moderate COPD: age \<75 years, FEV1/FVC\<70%, FEV1 predicted value ≥50%